Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ...
One major reason for the high cost of developing new drugs and other chemicals is the sheer number of experiments involved; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback